Applied NeuroSolutions Renews Drug Discovery Collaboration Lilly
Eli Lilly (Lilly) has agreed to a one-year renewal of its drug discovery collaboration with Applied NeuroSolutions. Lilly is expected to pay $250,000 to Applied NeuroSolutions for the
AstraZeneca and Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing Pharmaceutical Group (CTTQ) have signed an exclusive licence agreement for TQC3721.